Meningococcal conjugate vaccines: optimizing global impact

References

• MillerESalisburyDRamsayMPlanning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success storyVaccine200120Suppl 1S58S6711587814
   PubMed Web of Science ®Google Scholar
• BrouwerMCTunkelARvan de BeekDEpidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitisClin Microbiol Rev201023346749220610819
   PubMed Web of Science ®Google Scholar
• HarrisonLHTrotterCLRamsayMEGlobal epidemiology of meningococcal diseaseVaccine200927Suppl 2B51B6319477562
   PubMed Web of Science ®Google Scholar
• CaugantDAPopulation genetics and molecular epidemiology of Neisseria meningitidisAPMIS199810655055259674888
   PubMed Web of Science ®Google Scholar
• CohnACMacNeilJRHarrisonLHChanges in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal diseaseClin Infect Dis201050218419120001736
   PubMed Web of Science ®Google Scholar
• CartwrightKAStuartJMJonesDMNoahNDThe Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamicaEpidemiol Infect19879935916013123263
   PubMed Web of Science ®Google Scholar
• CaugantDAHøibyEAMagnusPAsymptomatic carriage of Neisseria meningitidis in a randomly sampled populationJ Clin Microbiol19943223233308150942
   PubMed Web of Science ®Google Scholar
• ClausHMaidenMCMaagRFroschMVogelUMany carried meningococci lack the genes required for capsule synthesis and transportMicrobiology2002148Pt 61813181912055301
   PubMed Web of Science ®Google Scholar
• GoldschneiderIGotschlichECArtensteinMSHuman immunity to the meningococcus. I. The role of humoral antibodiesJ Exp Med19691296130713264977280
   PubMed Web of Science ®Google Scholar
• GotschlichECGoldschneiderIArtensteinMSHuman immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteersJ Exp Med19691296136713844977283
   PubMed Web of Science ®Google Scholar
• SantosGFDeckRRDonnellyJBlackwelderWGranoffDMImportance of complement source in measuring meningococcal bactericidal titersClin Diagn Lab Immunol20018361662311329468
   PubMedGoogle Scholar
• BorrowRBalmerPMillerEMeningococcal surrogates of protection – serum bactericidal antibody activityVaccine20052317–182222222715755600
   PubMed Web of Science ®Google Scholar
• BorrowRAndrewsNGoldblattDMillerESerological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protectionInfect Immun20016931568157311179328
   PubMed Web of Science ®Google Scholar
• AndrewsNBorrowRMillerEValidation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in EnglandClin Diagn Lab Immunol200310578078612965904
   PubMedGoogle Scholar
• GoldRArtensteinMSMeningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969–1970Bull WHO19714532792825316907
   PubMed Web of Science ®Google Scholar
• BiselliRFattorossiAMatricardiPMNisiniRStroffoliniTD’AmelioRDramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccinationVaccine19931155785818488715
   PubMed Web of Science ®Google Scholar
• GreenwoodBMHassan-KingMWhittleHCPrevention of secondary cases of meningococcal disease in household contacts by vaccinationBMJ19781612313171319417754
   PubMed Web of Science ®Google Scholar
• RosensteinNLevineOTaylorJPEfficacy of meningococcal vaccine and barriers to vaccinationJAMA199827964354399466635
   PubMed Web of Science ®Google Scholar
• MillerMAWengerJRosensteinNPerkinsBEvaluation of meningococcal meningitis vaccination strategies for the meningitis belt in AfricaPediatr Infect Dis J199918121051105910608623
   PubMed Web of Science ®Google Scholar
• SaliouPStoeckelPLafayeAReyJLRenaudetJControlled tests of anti-meningococcal polysaccharide A vaccine in the African Sahel area (Upper Volta and Mali)Dev Biol Stand19784197108 French.572789
   PubMedGoogle Scholar
• IsmailAHarrisSGranoffDSerum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemicPediatr Infect Dis J200423874875515295225
   PubMed Web of Science ®Google Scholar
• KellyDPollardAMoxonERImmunological memory: the role of B cells in long-term protection against invasive bacterial pathogensJAMA2005294233019302316414950
   PubMed Web of Science ®Google Scholar
• KellyDSnapeMDClutterbuckEACRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cellsBlood200610882642264716675705
   PubMed Web of Science ®Google Scholar
• GoldRLepowMLGoldschneiderIDraperTFGotshlichECKinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and childrenJ Infect Dis19791405690697118997
   PubMed Web of Science ®Google Scholar
• ReingoldALBroomeCVHightowerAWAge-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccineLancet1985284471141182862316
   PubMed Web of Science ®Google Scholar
• GoldRLepowMLGoldschneiderIDraperTLGotschlichECClinical evaluation of group A and group C meningococcal polysaccharide vaccines in infantsJ Clin Invest1975566153615471202084
   PubMed Web of Science ®Google Scholar
• BorrowRJosephHAndrewsNReduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adultsVaccine2000199–101129113211137248
   PubMed Web of Science ®Google Scholar
• MacLennanJObaroSDeeksJImmune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhoodVaccine19991723–243086309310462244
   PubMed Web of Science ®Google Scholar
• Hassan-KingMKWallRAGreenwoodBMMeningococcal carriage, meningococcal disease and vaccinationJ Infect198816155593130424
   PubMed Web of Science ®Google Scholar
• BlakebroughISGreenwoodBMWhittleHCBradleyAKGillesHMFailure of meningococcal vaccination to stop the transmission of meningococci in Nigerian schoolboysAnn Trop Med Parasitol19837721751786349560
   PubMed Web of Science ®Google Scholar
• PollardAJPerrettKPBeverleyPCMaintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccinesNat Rev Immunol20099321322019214194
   PubMed Web of Science ®Google Scholar
• AucklandCGraySBorrowRClinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United KingdomJ Infect Dis2006194121745175217109348
   PubMed Web of Science ®Google Scholar
• FairleyCKBeggNBorrowRFoxAJJonesDMCartwrightKConjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infantsJ Infect Dis19961746136013638940235
   PubMed Web of Science ®Google Scholar
• LiebermanJMChiuSSWongVKSafety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trialJAMA199627519149915038622225
   PubMed Web of Science ®Google Scholar
• LakshmanRJonesIWalkerDSafety of a new conjugate meningococcal C vaccine in infantsArch Dis Child200185539139711668101
   PubMed Web of Science ®Google Scholar
• BramleyJCHallTFinnASafety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of ageVaccine20011920–222924293111282204
   PubMed Web of Science ®Google Scholar
• MacLennanJMShackleyFHeathPTSafety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trialJAMA2000283212795280110838647
   PubMed Web of Science ®Google Scholar
• RichmondPBorrowRMillerEMeningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memoryJ Infect Dis199917961569157210228085
   PubMed Web of Science ®Google Scholar
• GoldblattDBorrowRMillerENatural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adultsJ Infect Dis2002185339740011807724
   PubMed Web of Science ®Google Scholar
• ChooSZuckermanJGoilavCHatzmannEEverardJFinnAImmunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A + C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trialVaccine200018242686269210781855
   PubMed Web of Science ®Google Scholar
• EnglishMMacLennanJMBowen-MorrisJMA randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infantsVaccine2000199–101232123811137262
   PubMed Web of Science ®Google Scholar
• SchmittHJSteulKSBorkowskiACeddiaFYpmaEKnufMTwo versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infantsVaccine200826182242225218407386
   PubMed Web of Science ®Google Scholar
• BorrowRGoldblattDFinnAImmunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United KingdomInfect Immun200371105549555514500473
   PubMed Web of Science ®Google Scholar
• SigurdardottirSTDavidsdottirKArasonVASafety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary dosesVaccine200826334178418618606481
   PubMed Web of Science ®Google Scholar
• BorrowRGoldblattDFinnAAntibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United KingdomJ Infect Dis200218691353135712402208
   PubMed Web of Science ®Google Scholar
• PerrettKPWinterAPKibwanaEAntibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999–2000 and response to a booster: a phase 4 clinical trialClin Infect Dis201050121601161020459323
   PubMed Web of Science ®Google Scholar
• SakouIITzanakakiGTsoliaMNInvestigation of serum bactericidal activity in childhood and adolescence 3–6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccineVaccine200927334408441119500554
   PubMed Web of Science ®Google Scholar
• SnapeMDKellyDFGreenBMoxonERBorrowRPollardAJLack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccinePediatr Infect Dis J200524212813115702040
   PubMed Web of Science ®Google Scholar
• BorrowRAndrewsNFindlowHKinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccineClin Vaccine Immunol201017115415919906895
   PubMed Web of Science ®Google Scholar
• SnapeMDKellyDFSaltPSerogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunizationClin Infect Dis200643111387139417083009
   PubMed Web of Science ®Google Scholar
• SnapeMDKellyDFLewisSSeroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational studyBMJ200833676591487149118535032
   PubMed Web of Science ®Google Scholar
• KeyserlingHPapaTKoranyiKSafety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescentsArch Pediatr Adolesc Med20051591090791316203934
   PubMed Web of Science ®Google Scholar
• CampbellJDEdelmanRKingJCJrPapaTRyallRRennelsMBSafety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adultsJ Infect Dis2002186121848185112447774
   PubMed Web of Science ®Google Scholar
• PichicheroMCaseyJBlatterMComparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old childrenPediatr Infect Dis J2005241576215665711
   PubMed Web of Science ®Google Scholar
• JacksonLABaxterRReisingerKPhase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescentsClin Infect Dis2009491e1e1019476428
   PubMed Web of Science ®Google Scholar
• ReisingerKSBaxterRBlockSLShahJBedellLDullPMQuadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, MenactraClin Vaccine Immunol200916121810181519812260
   PubMed Web of Science ®Google Scholar
• HalperinSADiaz-MitomaFDullPAnemonaACeddiaFSafety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlersEur J Clin Microbiol Infect Dis201029325926720033465
   PubMed Web of Science ®Google Scholar
• VuDMWelschJAZuno-MitchellPDela CruzJVGranoffDMAntibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccineJ Infect Dis2006193682182816479517
   PubMed Web of Science ®Google Scholar
• GillCJBaxterRAnemonaACiavarroGDullPPersistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescentsHum Vaccin201061188188721339701
   PubMed Web of Science ®Google Scholar
• GranoffDMHarrisSLProtective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccinePediatr Infect Dis J200423649049715194828
   PubMed Web of Science ®Google Scholar
• GranoffDMMorganAWelschJAImmunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old childrenVaccine200523344307431415921829
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Updated recommendations for use of meningococcal conjugate vaccines – Advisory Committee on Immunization Practices (ACIP), 2010MMWR Morb Mortal Wkly Rep2011603727621270745
   PubMedGoogle Scholar
• Meningitis Vaccine ProjectVaccine introduction strategy Available at: http://www.meningvax.org/vaccine-introduction.php. Accessed May 24, 2011.
   Google Scholar
• FindlowHPlikaytisBDAaseAInvestigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adultsClin Vaccin Immunol2009167969977
   Google Scholar
• KshirsagarNMurNThatteUSafety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adultsVaccine200725Suppl 1A101A10717532101
   PubMed Web of Science ®Google Scholar
• BorrowRFoxAJRichmondPCInduction of immunological memory in UK infants by a meningococcal A/C conjugate vaccineEpidemiol Infect2000124342743210982066
   PubMed Web of Science ®Google Scholar
• RichmondPBorrowRGoldblattDAbility of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlersJ Infect Dis2001183116016311078484
   PubMed Web of Science ®Google Scholar
• MacLennanJObaroSDeeksJImmunologic memory 5 years after meningococcal A/C conjugate vaccination in infancyJ Infect Dis200118319710411087205
   PubMed Web of Science ®Google Scholar
• McVernonJMaclennanJButteryJOsterPDanzigLMoxonERSafety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old childrenPediatr Infect Dis J200221874775312192163
   PubMed Web of Science ®Google Scholar
• McVernonJMacLennanJPollardAJImmunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four yearsPediatr Infect Dis J200322765966112886896
   PubMed Web of Science ®Google Scholar
• Blanchard RohnerGSnapeMDKellyDFThe magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster responseJ Immunol200818042165217318250423
   PubMed Web of Science ®Google Scholar
• de VoerRMvan der KlisFREngelsCWKinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adultsVaccine200927506974698219800445
   PubMed Web of Science ®Google Scholar
• BettingerJAScheifeleDWLe SauxNHalperinSAVaudryWTsangRCanadian Immunization Monitoring Program, Active (IMPACT)The impact of childhood meningococcal serogroup C conjugate vaccine programs in CanadaPediatr Infect Dis J200928322022419209096
   PubMed Web of Science ®Google Scholar
• KafetzisDAStamboulidisKNTzanakakiGMeningococcal group C disease in Greece during 1993–2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatriciansClin Microbiol Infect200713555055217378929
   PubMed Web of Science ®Google Scholar
• CanoRLarrauriAMateoSAlcaláBSalcedoCVázquezJAImpact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decisionEuro Surveill200497111515318008
   PubMedGoogle Scholar
• SallerasLDominguezACardenosaNImpact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in SpainVaccine2003217–872572812531349
   PubMed Web of Science ®Google Scholar
• BooyRJelfsJEl BashirHNissenMDImpact of meningococcal C conjugate vaccine use in AustraliaMed J Aust2007186310810917309394
   PubMed Web of Science ®Google Scholar
• De GreeffSCde MelkerHESpanjaardLSchoulsLMvan DerendeAProtection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the NetherlandsPediatr Infect Dis J2006251798016395110
   PubMed Web of Science ®Google Scholar
• Wiese-PosseltMHellenbrandWSiedlerAMayerCUniversal childhood immunisation with pneumococcal vaccine and meningococcal serogroup C vaccine introduced in GermanyEuro Surveill2006119E06090717075143
   PubMedGoogle Scholar
• National Advisory Committee on Immunization (NACI)Meningococcal C conjugate vaccination recommendations for infants. an Advisory Committee Statement (ACS)Can Commun Dis Rep200733ACS–11112
   Google Scholar
• BilukhaOORosensteinNPrevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR Recomm Rep200554RR–712115917737
   PubMedGoogle Scholar
• TrotterCLAndrewsNJKaczmarskiEBMillerERamsayMEEffectiveness of meningococcal serogroup C conjugate vaccine 4 years after introductionLancet2004364943136536715276396
   PubMed Web of Science ®Google Scholar
• RamsayMEAndrewsNKaczmarskiEBMillerEEfficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in EnglandLancet2001357925119519611213098
   PubMed Web of Science ®Google Scholar
• LarrauriACanoRGarcíaMMateoSImpact and effectiveness of meningococcal C conjugate vaccine following its introduction in SpainVaccine200523324097410015908059
   PubMed Web of Science ®Google Scholar
• SallerasLDominguezACardenosaNDramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccineVaccine2003217–872973312531350
   PubMed Web of Science ®Google Scholar
• MaidenMCIbarz-PavónABUrwinRImpact of meningococcal serogroup C conjugate vaccines on carriage and herd immunityJ Infect Dis2008197573774318271745
   PubMed Web of Science ®Google Scholar
• CohnAOptimizing the Adolescent Meningococcal Vaccination Programpresented at ACIPOctober 2010 Available at: http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct10/02-5-mening-mcv4.pdf. Accessed July 13, 2011.
   Google Scholar
• CampbellHAndrewsNBorrowRTrotterCMillerEUpdated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityClin Vaccine Immunol201017584084720219881
   PubMed Web of Science ®Google Scholar
• TrotterCLBorrowRFindlowJSeroprevalence of antibodies against serogroup C meningococci in England in the postvaccination eraClin Vaccine Immunol200815111694169818827191
   PubMed Web of Science ®Google Scholar
• KinlinLMJamiesonFBrownEMRapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000–2006Vaccine200927111735174019186206
   PubMed Web of Science ®Google Scholar
• TrotterCLRamsayMEGraySFoxAKaczmarskiENo evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and WalesLancet Infect Dis2006610616617 author reply61761817008169
   PubMed Web of Science ®Google Scholar
• DiggleMAClarkeSCIncreased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccinesJ Clin Microbiol20054394649465316145121
   PubMed Web of Science ®Google Scholar
• GranoffDMHarrisonLBorrowRMeningococcal vaccinesVaccinesPlotkinSOrensteinWOffetPPhiladelphia, PASaunders2008399434
   Google Scholar
• Department of HealthImmunisation against infectious disease –‘The Green Book’Norwich, UKTSO2006
   Google Scholar
• WhiteCPScottJMeningococcal serogroup C conjugate vaccination in Canada: how far have we progressed? How far do we have to go?Can J Public Health20101011121420364530
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians of Ireland (RCPI)Immunisation guidelines for Ireland: menigococcal infectionsDublinm, IrelandRCPI2008
   Google Scholar
• Network, EUIBIS 2009; Available at: http://www.hpa-bioinformatics.org.uk/euibis/meningo/vacc_sched_meningo.htm. Accessed July 13, 2011.
   Google Scholar